2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4127 Incorporating the MYC 5’-UTR sequence improves the efficacy of CD19-directed CAR T cells

Lishi Xie, PhD, Xiufen Chen, PhD2, Sidney Wang3, Justin Kline, MD4
1 The University of Chicago, Chicago, Illinois, United States
2 The University of Chicago, Chicago, Illinois, United States
3 The University of Chicago, Chicago, Illinois, United States
4 The University of Chicago, Chicago, Illinois, United States

Introduction

Chimeric antigen receptor (CAR) T cell therapy has significantly improved outcomes for patients with relapsed and refractory (r/r) B-cell lymphomas. However, most patients ultimately relapse. Evidence suggests that CAR T cells enriched for early memory-like phenotypes yield superior clinical outcomes. Recent single cell analyses support a model in which asymmetric cell division (ACD) preserves T cell memory: the daughter cell proximal to the antigen-presenting cell (APC) receives stronger TCR signals, leading to high c-Myc translation and an effector fate, while the distal cell adopts a memory fate with lower c-Myc expression. We hypothesized that coupling CAR expression with c-Myc protein translation could promote ACD and memory phenotype of CAR T cells. Inspired by prior work indicating that the promoter-2 leading (P2L) sequence located on 5’-UTR of c-Myc mRNA enhances c-Myc protein translation, we incorporated the P2L sequence into the 5’-UTR of CAR mRNA, aiming to enhance CAR protein expression and effector function in proximal daughter cells while maintaining the memory fate of distal daughter cells with low CAR protein expression.

Methods

Human or mouse P2L sequence was inserted between the CAR promoter and CDS. CD19 expressing OCI-Ly8 human DLBCL cells served as targets for evaluating CAR-T efficacy both in vitro and in vivo. Survival of immunodeficient NSG mice was measured after CAR-T cell infusion 7 days post tumor graft. Mouse CAR-T function was monitored via circulating B cells in immunocompetent C57BL/6 mice infused with CAR-T after lymphodepletion.

Results

In vitro, P2L-CAR T cells demonstrated enhanced cytolytic activity against OCI-Ly8 lymphoma cells, indicating superior effector cell function. Furthermore, P2L-CAR T cells exhibited sustained tumor cells killing upon repeated antigen exposure, suggesting enhanced memory cell function. In vivo, infusion of P2L CD28z CAR T cells significantly prolonged survival in NSG mice bearing OCI-Ly8 xenografts (median survival not reached vs. 45 days; p < 0.0023). Given the 72% sequence similarity between human and mouse P2L, we further evaluated mouse P2L (mP2L) CAR T cells in immunocompetent mice. In C57BL/6 mice, mP2L-CAR T cells targeting murine Cd19 induced durable B cell aplasia (> 50 days), indicating persistent CAR-T activity. Mechanistically, P2L increased cell CAR protein expression and surface localization. Upon antigen stimulation, P2L-CAR T cells demonstrated enhanced immunological synapse formation and degranulation. Furthermore, tumor-activated P2L-CAR T cells also showed elevated expression of effector-related genes, such as TNF-α, IL-2, IFN-γ, and perforin.

Conclusions

Incorporating the c-Myc P2L 5’-UTR sequence into CAR 5’-UTR enhances CAR protein expression, effector function, and therapeutic efficacy both in vitro and in vivo. Ongoing studies aim to elucidate the role of P2L in promoting CAR T cell persistence and memory differentiation via ACD.

Lishi Xie, PhD: No relevant conflicts of interest to declare.